drugset / Trial / NCT00414284
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels. This study will also look at the pharmacokinetic data (amount of Kaletra in blood at different times).
Timeline
- Start
- 2006-06
- Primary completion
- 2007-04
- Completion
- 2007-04
Outcome
Outcome not reported
Stopped: “One subject's HIV RNA rebounded at week 12. A repeat PhenoSense GT combination resistance assay at week 12 revealed evolution in protease inhibitor resistance.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 600 mg | — |
| Subject | Lopinavir | Other / unclassified | 800 mg | — |
| Subject | Ritonavir | Other / unclassified | 150 mg | — |
| Subject | Ritonavir | Other / unclassified | 200 mg | — |